Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biopharmaceutical company Healthpoint Biotherapeutics has announced the results for its Phase 2b clinical trial investigating the efficacy of HP802-247 in venous leg ulcers, which is published in journal The Lancet .
Subscribe to our email newsletter
HP802-247 is an investigational allogeneic living cell bioformulation that contains keratinocytes and fibroblasts currently under development for venous leg ulcers treatment.
Healthpoint Biotherapeutics chief medical officer Bert Slade said, "We are very pleased that the trial results are appearing in such a prestigious general medical journal, thus recognizing the impact chronic wounds have across multiple medical specialties."
The Phase 2b trial has been designed to know the effectiveness of two cell concentrations and two dosing frequencies of HP802-247, when combined with standard care, compared to control plus standard care, in healing venous leg ulcers over a 12-week treatment period.
The randomized, double blind, dose-finding study enrolled 228 subjects across 35 investigational centers in the US.
Venous Leg Ulcers are caused by swelling and inflammation secondary to blockage or backflow in the veins of the legs.
The study results are also accompanied by expert commentary commissioned by the journal.